Objective: A novel, inhalation-driven, multidose dry powder inhaler (MDPI) eliminates the
need to coordinate actuation with inhalation. To characterize dose response, efficacy, and …

Methods This phase 3, double-blind, parallel-group study (FSS-AS-30017; NCT02141854)
evaluated asthmatic patients (ages≥ 12 years) previously taking inhaled corticosteroids …

Methods This phase 3, double-blind, parallel-group study (FSS-AS-301; NCT02139644)
evaluated asthmatic patients (ages≥ 12 years) using inhaled corticosteroids (ICS) or …

Note: This is the first aerosol metered-dose inhaler to deliver medication that uses
hydrofluoroalkane as a propellant, which enables medication to reach smaller airways. It …

The Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee
(PADAC) has voted 16 to 1 that the data support a favourable benefit risk assessment for the …

Aim To compare salmeterol (SALM) and fluticasone propionate (FP) systemic exposure
following inhaled salmeterol/fluticasone propionate combination (SFC) from a unit-dose …

Revolizer® is a single dose dry powder inhaler (SDDPI) with moderate resistance, which
requires a simple inhalation technique. We report here for the first-time results of …

ABSTRACT Objective: Evaluate fluticasone propionate (Fp) using a novel, inhalation-driven,
multidose dry powder inhaler (MDPI) in patients with severe persistent asthma, versus …

Background: This report presents results of the first human study of a new dry powder
inhaler (DPI-C). DPI-C uses reverse flow cyclone technology to retain larger particles in the …

Methods Multicenter, single-arm, stratified, open-label, randomized, placebo study. Children
(5–7 and 8–11 years of age), continuing their usual inhaled asthma medication, were …